Will Pfizer's Ibrance sales exceed $5 billion annually by end of 2025? | Binary | | | 11 days ago | |
Will Ibrance receive FDA approval for expanded use in HR+, HER2+ metastatic breast cancer by end of 2025? | Binary | | | 11 days ago | |
Will Novartis receive FDA approval for Baiyu's cancer drug by end of 2025? | Binary | | | 2 months ago | |
Market share of Baiyu's cancer drug in Novartis' oncology portfolio by 2026? | Categorical | | | 2 months ago | |
Total milestone payments made by Novartis to Baiyu by end of 2025? | Categorical | | | 2 months ago | |
Will Kisqali receive full EU approval for HR+/HER2- early breast cancer by end of 2025? | Binary | | | 2 months ago | |
Will Novartis make the first milestone payment to Baiyu by end of 2025? | Binary | | | 2 months ago | |
Will Novartis report revenue growth in 2025 due to Kisqali approval? | Binary | | | 3 months ago | |
How many new prescriptions for Kisqali will be issued by the end of Q2 2025? | Categorical | | | 3 months ago | |
How will Novartis' stock performance compare to its competitors by the end of Q1 2025? | Categorical | | | 3 months ago | |
What will be the percentage increase in Kisqali prescriptions in the US by the end of Q1 2025? | Categorical | | | 3 months ago | |
Will Kisqali be approved by the EMA for early-stage breast cancer by the end of 2024? | Binary | | | 3 months ago | |
Will Novartis's stock price increase by more than 10% by the end of 2024 due to Kisqali's expanded approval? | Binary | | | 3 months ago | |
Which region will approve Ibrance for expanded use in HR+, HER2+ metastatic breast cancer by end of 2025? | Categorical | | | 11 days ago | |
Will Ibrance surpass Kisqali in market share for HR+, HER2+ metastatic breast cancer by end of 2025? | Binary | | | 11 days ago | |
Which company will announce the next breakthrough in HR+, HER2+ metastatic breast cancer by end of 2025? | Categorical | | | 11 days ago | |
What will be the percentage increase in Ibrance's market share for HR+, HER2+ metastatic breast cancer by end of 2025? | Categorical | | | 11 days ago | |
Which region will see the first launch of Baiyu's cancer drug by Novartis by end of 2025? | Categorical | | | 2 months ago | |
How will competitors respond to Kisqali's FDA approval by the end of 2024? | Categorical | | | 3 months ago | |
Will Kisqali be included in new clinical guidelines for breast cancer treatment by the end of 2024? | Binary | | | 3 months ago | |
Will Kisqali's market share in the breast cancer treatment market increase by the end of Q1 2025? | Binary | | | 3 months ago | |
Which region will have the highest increase in Kisqali sales by the end of 2024? | Categorical | | | 3 months ago | |
What will be the overall market share of Kisqali in the HR+/HER2- breast cancer drug market by the end of 2024? | Categorical | | | 3 months ago | |
Will Kisqali's approval be expanded to additional stages of breast cancer by the end of 2024? | Binary | | | 3 months ago | |
